Cargando…
INSPIRE: Safety and tolerability of inhaled Yutrepia (treprostinil) in pulmonary arterial hypertension (PAH)
The INSPIRE trial was a Phase 3, open‐label, multicenter trial (LTI‐301) that enrolled patients with pulmonary arterial hypertension (PAH) ≥ 18 years of age who transitioned to Yutrepia from nebulized treprostinil (Transition) or added Yutrepia to prostacyclin naïve patients on ≤2 nonprostacyclin or...
Autores principales: | Hill, Nicholas S., Feldman, Jeremy P., Sahay, Sandeep, Benza, Raymond L., Preston, Ioana R., Badesch, David, Frantz, Robert P., Patel, Savan, Galloway, Ashley, Bull, Todd M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9400582/ https://www.ncbi.nlm.nih.gov/pubmed/36034402 http://dx.doi.org/10.1002/pul2.12119 |
Ejemplares similares
-
Transitioning from parenteral treprostinil to inhaled treprostinil in patients with pulmonary arterial hypertension
por: Raina, Amresh, et al.
Publicado: (2013) -
Characterisation of cough evoked by inhaled treprostinil and treprostinil palmitil
por: Chapman, Richard W., et al.
Publicado: (2021) -
Rapid Transition from Inhaled Iloprost to Inhaled Treprostinil in Patients with Pulmonary Arterial Hypertension
por: Bourge, Robert C, et al.
Publicado: (2013) -
An Event-driven Trial for Oral Treprostinil. Progress but Not the
Holy Grail
por: Hill, Nicholas S., et al.
Publicado: (2020) -
Inhaled treprostinil: a therapeutic review
por: Channick, Richard N, et al.
Publicado: (2012)